113 Data are presented as proportions n with corresponding percentages (%) or as median [interquartile range, IQR] for continuous variables. P-values ≤ 0.05 were considered statistically significant. †Use of TNF-α-antagonists included use of the following compounds: infliximab, adalimumab, golimumab and certolizumab pegol. Abbreviations: BMI, body-mass index; CD, Crohn’s disease; GI, gastrointestinal; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; SCCAI, Simple Clinical Colitis Activity Index; TNF-α, tumor necrosis factor alpha; UC, ulcerative colitis. The antibody epitope repertoire in IBD E2 (left-sided colitis) - - 63 (30.4) E3 (pancolitis) - - 118 (57.0) Medication use, n (%) 496 (99.8) 255 (99.6) 207 (100) Aminosalicylates 193 (38.8) 27 (10.6) 143 (69.1) <0.001 Thiopurines 189 (38.0) 113 (44.3) 68 (32.9) 0.012 Steroids 119 (23.9) 61 (23.9) 49 (23.7) 0.950 Calcineurin inhibitors 8 (1.6) 1 (0.4) 7 (3.4) 0.025 Methotrexate 38 (7.6) 31 (12.2) 4 (1.9) <0.001 TNF-α-antagonists† 120 (24.1) 98 (38.4) 18 (8.7) <0.001 Disease activity score 355 (71.4) HBI (CD), n (%) - 170 (66.4) - Remission (<5) - 104 (61.1) - Mild disease (5-7) - 29 (17.1) - Moderate disease (8-16) - 35 (20.6) - Severe disease (>16) - 2 (1.2) - SCCAI (UC), n (%) - - 185 (89.4) Remission (≤2) - - 133 (71.9) Active disease (>2) - - 52 (28.1) CRP, n (%) 489 (98.4) 253 (98.8) 203 (98.1) 0.031 ≤ 5 mg/L 343 (69.0) 167 (66.0) 153 (75.4) > 5 mg/L 146 (29.4) 86 (34.0) 50 (24.6) Surgical history, n (%) 496 (99.8) 255 (99.6) 207 (100) Ileocecal resection 65 (13.1) 64 (25.1) 0 (0.0) <0.001 Colon resection (or partial) 65 (13.1) 34 (13.3) 28 (13.5) 0.952 Data are presented as proportions n with corresponding percentages (%) or as median [interquartile range, IQR] for continuous variables. P-values ≤ 0.05 were considered statistically significant. †Use of TNF-α-antagonists includ d use of the foll wing compou ds: infliximab, adalimumab, golimumab and certolizumab pegol. Abbreviations: BMI, body-mass index; CD, Crohn’s disease; GI, gastrointestinal; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; SCCAI, Simple Clinical Colitis Activity Index; TNF-α, tumor necrosis factor alpha; UC, ulcerative colitis.
RkJQdWJsaXNoZXIy MjY0ODMw